AELIX and Gilead to trial new HIV regimen

Gilead Sciences (Nasdaq: GILD) is to collaborate with Spain's AELIX Therapeutics, a spin-off of the HIVACAT vaccine research consortium, on the development of investigational products aimed at curing HIV infection.

The firms will kick off a clinical study, AELIX-003, which will explore a regimen containing AELIX Therapeutics’ HTI T-cell vaccine and Gilead´s TLR7 agonist, vesatolimod, in HIV-infected people.

The study, which is slated to begin at the start of next year, will enroll around 90 participants who have started antiretroviral therapy during early HIV infection, at various clinical trial sites in Spain.